Pandya Rajan, Sundaram Ponraj Kamatchi, Baghel Shashank Singh
Department of Neurosurgery, Goa Medical College, Panaji, Goa, India.
Asian J Neurosurg. 2024 Sep 10;19(4):728-734. doi: 10.1055/s-0044-1790516. eCollection 2024 Dec.
Early posttraumatic seizures (EPTS) are a major complication after a head injury, defined as seizures developing within the first 7 days of trauma. Levetiracetam has become a popular drug for the prevention of posttraumatic seizures in institutions worldwide. However, it has been reportedly associated with adverse effects like behavioral changes and somnolence. This study aimed to compare the efficacy of a newer drug, brivaracetam, which is reported to have a better pharmacokinetic profile. These findings may be significant in providing a safer yet efficacious alternative to levetiracetam. The aim of this study was to evaluate the efficacy of brivaracetam for prophylaxis of EPTS and to compare it with levetiracetam. A prospective, single-blind, parallel-group (alternate allocation) controlled trial over 100 patients admitted with traumatic brain injury in the Department of Neurosurgery, Goa Medical College, Panaji, Goa, India. The data was analyzed using IBM SPSS Statistics 29.0. Twenty patients developed EPTS in the study group: 8 from the group receiving brivaracetam and 12 from the group receiving levetiracetam. Although the brivaracetam group had a lower incidence of EPTS, the difference was not statistically significant. Eleven patients from the levetiracetam group developed side effects, while six patients from the brivaracetam group had side effects. There was no significant difference in the incidence of side effects. Brivaracetam has efficacy equal to that of levetiracetam for prophylaxis of EPTS.
早期创伤后癫痫(EPTS)是头部受伤后的一种主要并发症,定义为在创伤后的前7天内发生的癫痫。左乙拉西坦已成为全球各机构预防创伤后癫痫的常用药物。然而,据报道它与行为改变和嗜睡等不良反应有关。本研究旨在比较一种新药布瓦西坦的疗效,据报道布瓦西坦具有更好的药代动力学特征。这些发现对于提供一种比左乙拉西坦更安全且有效的替代药物可能具有重要意义。 本研究的目的是评估布瓦西坦预防EPTS的疗效,并将其与左乙拉西坦进行比较。 一项前瞻性、单盲、平行组(交替分配)对照试验,纳入了印度果阿邦帕纳吉市果阿医学院神经外科收治的100例创伤性脑损伤患者。使用IBM SPSS Statistics 29.0对数据进行分析。 研究组中有20例患者发生了EPTS:8例来自接受布瓦西坦治疗的组,12例来自接受左乙拉西坦治疗的组。尽管布瓦西坦组的EPTS发病率较低,但差异无统计学意义。左乙拉西坦组有11例患者出现副作用,而布瓦西坦组有6例患者出现副作用。副作用发生率无显著差异。 布瓦西坦在预防EPTS方面的疗效与左乙拉西坦相当。